Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States
Cancer · 2025
DOI: 10.1002/cncr.35795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Nikhil T Sebastian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Health Expenditures, Health Care Costs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Prostate Cancer Foundation, NIH HHS.
Abstract (Originalsprache)
Background
Radical prostatectomy (RP) and radiotherapy (RT) are standard‐of‐care treatments for localized prostate cancer. The authors studied the utilization and total health care and patient‐incurred costs of RP and RT in the United States using the Merative MarketScan Medicare (Medicare Supplemental and Coordination of Benefits [MDCR]) and Commercial (Commercial Claims and Encounters [CCAE]) databases.
Methods
Men were identified who had nonmetastatic prostate cancer treated with RP, external‐beam RT (EBRT), brachytherapy (BT), EBRT combined with BT (EBRT + BT), stereotactic body RT (SBRT), or proton‐beam therapy (PBT) between 2009 and 2022. Year‐to‐year treatment utilization was compared using the Kendall Tau‐b test. Mean total health care and patient out‐of‐pocket costs within 12 months of treatment were compared using the Kruskal–Wallis test.
Results
In the MDCR database, 44,937 patients were identified who received treatment with RP ( n = 12,879), EBRT ( n = 26,193), BT ( n = 926), EBRT + BT ( n = 4706), PBT ( n = 57), or SBRT ( n = 176). Between 2009 and 2021, EBRT use increased from 52.5% to 62.2% ( p for trend < .001), SBRT increased from 0.4% to 0.5% ( p < .001), BT decreased from 3.1% to 1.0% ( p < .001), and EBRT + BT decreased from 14.8% to 6.8% ( p < 0.001); whereas use remained similar for RP (from 29.1% to 29.4%; p = .82) and PBT (from 0.1% to 0.1%; p = .93). In the CCAE database, 75,626 patients were identified who received treatment with RP ( n = 50,278), EBRT ( n = 16,985), BT ( n = 1243), EBRT + BT ( n = 6811), PBT ( n = 92), or SBRT ( n = 217). EBRT use increased from 20.0% to 24.9% ( p < .001), SBRT increased from 0.1% to 0.8% ( p < .001), BT decreased from 2.5% to 0.7% ( p < .001), and EBRT + BT decreased from 10.6% to 7.4% ( p < .001); whereas use remained similar for RP (from 66.8% to 66.1%; p for trend = .82), and PBT (from 0.1% to 0.1%; p for trend = .76). In the MDCR and CCAE databases, PBT had the highest total cost, whereas BT had the lowest.
Conclusions
Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Department of Urology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Nikhil T Sebastian, Dattatraya Patil, C Adam Lorentz, Shreyas S Joshi
Förderung
- Prostate Cancer Foundation
- NIH HHS
Zitieren
APA
Sebastian, N. T., Patil, D., Patel, P. R., Jani, A. B., Hershatter, B. W., Dhere, V. R., Godette, K. D., Lorentz, C. A., Weiss, A. D., Joshi, S. S., Sanda, M. G., & Patel, S. A. (2025). Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer. https://doi.org/10.1002/cncr.35795
Vancouver
Sebastian NT, Patil D, Patel PR, Jani AB, Hershatter BW, Dhere VR, et al. Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer. 2025. doi:10.1002/cncr.35795
BibTeX
@article{Sebastian2025,
author = {Sebastian, Nikhil T and Patil, Dattatraya and Patel, Pretesh R and Jani, Ashesh B and Hershatter, Bruce W and Dhere, Vishal R and Godette, Karen D and Lorentz, C Adam and Weiss, Aaron D and Joshi, Shreyas S and Sanda, Martin G and Patel, Sagar A},
title = {Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35795}
}
EUVIMED